207_Combined course Presentations

Toxicity of concurrent SRT and antibody therapy

Anti-VEGF (bevacizumab)

 additional risk of concurrent cranial SRT and bevacizumab is small (neurological toxicity)

 possibly protective to the development of radionecrosis.

 combination of bevacizumab and extra-cranial SBRT: scarce data

 concurrent abdominal SRT and bevacizumab should be practised with caution.

Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37